$19.75
-0.25 (-1.25%)
Open$20.00
Previous Close$20.00
Day High$20.04
Day Low$18.64
52W High$28.00
52W Low$6.67
Volume—
Avg Volume926.2K
Market Cap1.34B
P/E Ratio—
EPS$-3.06
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+85.7% upside
Current
$19.75
$19.75
Target
$36.67
$36.67
$19.65
$36.67 avg
$47.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 85.08M | 76.59M | 82.32M |
| Net Income | 21.83M | 19.00M | 17.76M |
| Profit Margin | 25.7% | 24.8% | 21.6% |
| EBITDA | 33.39M | 28.41M | 32.89M |
| Free Cash Flow | 16.91M | 11.51M | 18.65M |
| Rev Growth | +15.3% | +2.7% | +8.4% |
| Debt/Equity | 0.18 | 0.16 | 0.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |